Herbst Kinsky advised its long-time client Themis Bioscience GmbH in course of a series B financing round with an impressive volume around EUR 10 Mio. Prominent investors in this round are Wellington Partners, Ventech Capital, Omnes Capital and der aws Gründerfonds.

Themis Bioscience is an international biotech company that successfully develops vaccines against emerging and specialist indications. The fresh capital will be used to complete a phase 2 clinical trial of its lead product, a vaccine candidate against Chikungunya fever. Exploiting the full potential of its proprietary Themaxyn® platform Themis is able to identify and rapidly advance vaccine candidates at various stages of development. Based on a well-proven base technology, the Themaxyn® platform offers both, an excellent safety profile and a validated manufacturing process. Both characteristics make Themis vaccine candidates highly desirable. Out-licensing and different forms of partnering are preferred offers to companies that are interested in innovative manufacturing and would like to share the success of our Themaxyn® platform.

Dr. Erich Tauber, CEO and co-founder of Themis, on the successful completion of the company’s second financing round: “We are delighted about the continuous trust of our existing investors and of Austria’s leading Venture Fund aws Gruenderfonds. This trust and our recent excellent product development and technology progress have also attracted new investors and we are very grateful for their support.

Herbst Kinsky´s team was led by partner Florian Steinhart. Further members of the team have been David Pachernegg and Florian Pollak (Corporate).